More than 130 suppliers
ISO certified
In-house tech support
we Connect you
Bio-Connect
ProductsBack/NVP-BEZ235 [915019-65-7]
Chemical Structure
Chemical Structure
Chemical Structure

NVP-BEZ235 [915019-65-7]

Research Use Only
AG-CR1-3633
AdipoGen Life Sciences
CAS Number915019-65-7
DownloadMSDS
Product group Chemicals
Estimated Purity>98%
Molecular Weight469.5
Sign in to order and to see your custom pricing.
Large volume orders?
Order with a bulk request
More than 130 suppliers
ISO certified
In-house tech support

Overview

  • Supplier
    AdipoGen Life Sciences
  • Product Name
    NVP-BEZ235
  • Delivery Days Customer
    10
  • CAS Number
    915019-65-7
  • Certification
    Research Use Only
  • Estimated Purity
    >98%
  • Hazard Information
    Warning
  • Molecular Formula
    C30H23N5O
  • Molecular Weight
    469.5
  • Scientific Description
    Chemical. CAS: 915019-65-7. Formula: C30H23N5O. MW: 469.5. Potent dual ATP-competitive pan class I PI3K and mTOR inhibitor (p110alpha/gamma/delta/beta and mTOR(p70S6K) with IC50 of 4nM, 5nM, 7nM, 75nM and 6nM, respectively), subsequently inducing G1 phase arrest in biological cell growth and viability assays. Anticancer compound. Antiproliferative against several animal tumor cell lines, specifically blocking the dysfunctional activation of the PI3K pathway, Enhances the efficacy of other anticancer agents when used in in vivo combination studies. Strongly inhibits VEGF-induced cell proliferation and survival in vitro and VEGF-induced angiogenesis in vivo. Shown to be a potent inhibitor of ATM- and DNA-PKCs-mediated DNA damage and DNA double-strand break repair. Shown to have neuroprotective properties on amyloid-beta 1-42 induced neurotoxicity and memory impairment. Shows anti-trypanosomal activity for some selected species. - Potent dual ATP-competitive pan class I PI3K and mTOR inhibitor (p110alpha/gamma/delta/beta and mTOR(p70S6K) with IC50 of 4nM, 5nM, 7nM, 75nM and 6nM, respectively), subsequently inducing G1 phase arrest in biological cell growth and viability assays. Anticancer compound. Antiproliferative against several animal tumor cell lines, specifically blocking the dysfunctional activation of the PI3K pathway, Enhances the efficacy of other anticancer agents when used in in vivo combination studies. Strongly inhibits VEGF-induced cell proliferation and survival in vitro and VEGF-induced angiogenesis in vivo. Shown to be a potent inhibitor of ATM- and DNA-PKCs-mediated DNA damage and DNA double-strand break repair. Shown to have neuroprotective properties on amyloid-beta 1-42 induced neurotoxicity and memory impairment. Shows anti-trypanosomal activity for some selected species.
  • SMILES
    CN(C1=CN=C(C=CC(C2=CC(C=CC=C3)=C3N=C2)=C4)C4=C1N5C6=CC=C(C(C)(C)C#N)C=C6)C5=O
  • Storage Instruction
    -20°C,2°C to 8°C
  • UNSPSC
    12352200

References

  • Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity: S.M. Maira, et al.; Mol. Cancer Ther. 7, 1851 (2008)
  • Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging: C.R. Schnell, et al.; Cancer Res. 68, 6598 (2008)
  • NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations: V. Serra, et al.; Cancer Res 68, 8022 (2008)
  • Discovery of novel anticancer therapeutics targeting the PI3K/Akt/mTOR pathway: S.M. Maria, et al.; Future Med. Chem. 1, 137 (2009)
  • Targeting melanoma with dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors: R. Marone, et al.; Mol. Cancer Res. 7, 601 (2009)
  • Chiarini F, Grimaldi C, Ricci F, et al. Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia: F. Chiarini, et al.; Cancer Res. 70, 8097 (2010)
  • NVP-BEZ235, a dual pan class I PI3 kinase and mTOR inhibitor, promotes osteogenic differentiation in human mesenchymal stromal cells: S.K. Martin, et al.; J. Bone Miner. Res. 25, 2126 (2010)
  • Recent results in protein kinase inhibition for tropical diseases: D.P. Rotella, et al.; Bioorg. Med. Chem. Lett. 22, 6788 (2012)
  • The dual PI3K/mTOR inhibitor NVP-BEZ235 is a potent inhibitor of ATM- and DNA-PKCs-mediated DNA damage responses: B. Mukherjee, et al.; Neoplasia 14, 34 (2012)
  • Inhibition of autophagy as a strategy to augment radiosensitization by the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235: G.J. Cerniglia, et al.; Mol. Pharmacol. 82, 1230 (2012)